NASDAQ:INCY
Incyte Corporation Stock News
$54.08
+0.320 (+0.595%)
At Close: May 06, 2024
A Bear Market Rally or Markets Forming a Solid Base: 5 Picks
11:52am, Tuesday, 25'th Oct 2022 Zacks Investment Research
We have narrowed our search to five large-cap U.S. companies with strong potential for the rest of 2022. These are: IBKR, INCY, WMB, HUBB and LW.
A Bear Market Rally or Markets Forming a Solid Base: 5 Picks
09:02am, Tuesday, 25'th Oct 2022
We have narrowed our search to five large-cap U.S. companies with strong potential for the rest of 2022. These are: IBKR, INCY, WMB, HUBB and LW.
I Called This October Rally In August, Keep Your Seat Belts On
03:17am, Monday, 24'th Oct 2022 Seeking Alpha
After a barely discernible bottoming process, the rally has become obvious. Read more to see how I intend to take advantage of this rally.
Tracking Cathie Wood's ARK Invest 13F Portfolio - Q3 2022 Update
07:10am, Wednesday, 19'th Oct 2022 Seeking Alpha
ARK Invest’s 13F portfolio value decreased from $16.91B to $14.35B this quarter. Click to see the firm's trades for Q3 2022.
Expert Ratings for Incyte
08:05pm, Tuesday, 18'th Oct 2022 Benzinga
Incyte (NASDAQ:INCY) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
0
0
4
0
0
Last 30D
0
0
1
Analyst Thinks This Company's Bone Marrow Cancer Treatment Can 'Transform Paradigm'
05:59pm, Monday, 17'th Oct 2022 Benzinga
SVB Leerink initiated coverage on CTI Biopharma Corp (NASDAQ: CTIC) with an Outperform rating and a $13 price target.
CTIC is a commercial-stage biopharmaceutical company launching Vonjo — a d
Is Incyte (INCY) a Solid Growth Stock? 3 Reasons to Think "Yes"
04:45pm, Monday, 17'th Oct 2022 Zacks Investment Research
Incyte (INCY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
INCY vs. GMAB: Which Stock Is the Better Value Option?
03:40pm, Monday, 17'th Oct 2022 Zacks Investment Research
INCY vs. GMAB: Which Stock Is the Better Value Option?
Is Incyte (INCY) a Solid Growth Stock? 3 Reasons to Think "Yes"
03:03pm, Monday, 17'th Oct 2022
Incyte (INCY) is well positioned to outperform the market, as it exhibits above-average growth in financials.
Here's Why You Should Add Intra-Cellular Therapeutics (ITCI) Stock Now
02:43pm, Monday, 17'th Oct 2022 Zacks Investment Research
Intra-Cellular's (ITCI) product revenues are primarily driven by higher sales of its schizophrenia and bipolar disorder drug Caplyta. Caplyta is also being evaluated for other CNS indications.
INCY vs. GMAB: Which Stock Is the Better Value Option?
12:48pm, Monday, 17'th Oct 2022
INCY vs. GMAB: Which Stock Is the Better Value Option?
2 Cathie Wood Stocks That Are Beating the Market This Year
08:15pm, Friday, 07'th Oct 2022 The Motley Fool
One is doing much better than the other year to date, but they both have solid prospects ahead.
2 Cathie Wood Stocks That Are Beating the Market This Year
04:15pm, Friday, 07'th Oct 2022
One is doing much better than the other year to date, but they both have solid prospects ahead.
Incyte: A Biotech Stock With Improving Growth Prospects And A Favorable Chart
04:26pm, Thursday, 29'th Sep 2022
Biotech has pulled back sharply after a summer rebound, but the niche continues to outperform the S&P 500. One mid-sized biotech company is looking forward to better earnings ahead with a decent pipel
Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?
10:20am, Wednesday, 14'th Sep 2022 Zacks Investment Research
Smart Beta ETF report for RYH
